According to researchers at the Johns Hopkins University School of Medicine, Baltimore and faculty from the High-Value Practice Academic Alliance (HVPAA), Creatine kinase-myocardial band (CK-MB) is no longer an effective biomarker for detecting damaged myocardial tissue. Thus, this test can be safely eliminated from practice in the diagnosis of patients with suspected myocardial infarction (MI). Since 2014, guidelines from the American Heart Association have concluded that CK-MB provides no additional diagnostic value in diagnosing heart attacks.
They stated that troponin is the biomarker of choice as it has absolute myocardial tissue specificity and high clinical sensitivity for myocardial injury. With respect to the published safety outcome data, Multiple academic medical centers have eliminated the routine ordering of CK-MB tests. However, it is still ordered in many hospitals and…
